Back to Journals » Drug Design, Development and Therapy » Volume 13

Complement system and age-related macular degeneration: drugs and challenges

Authors Wu J, Sun X

Received 22 February 2019

Accepted for publication 1 July 2019

Published 19 July 2019 Volume 2019:13 Pages 2413—2425

DOI https://doi.org/10.2147/DDDT.S206355

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Sukesh Voruganti


Jiali Wu,1 Xiaodong Sun1–3

1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Shanghai Key Laboratory of Fundus Disease, Shanghai, People’s Republic of China; 3Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, People’s Republic of China

Abstract: Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of complement pathways involved in AMD and their therapies correspondingly. Finally, we discuss the development of the therapeutics existed now. Also, we enclose a list of drugs undergoing clinical trials.

Keywords: age-related macular degeneration, inflammation, complement system, immunotherapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]